TFX Teleflex (TFX) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000096943
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
200
13F, latest reported quarter
What the filings say about TFX
Congress, 1 year
No trades
Last one: sale, 2025-07-22
Teleflex insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for TELEFLEX INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.3% of the 6,005 shares held after it.
- 4 other insiders bought within 30 days.
- 200 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HAGGERTY GRETCHEN R bought about $23.0K of TFX on Aug 6, 2025; 4 other insiders bought within 30 days and 200 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.8% of the 6,305 shares held after it.
- 4 other insiders bought within 30 days.
- 200 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HAGGERTY GRETCHEN R bought about $34.4K of TFX on Aug 6, 2025; 4 other insiders bought within 30 days and 200 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 16, 2024.
- The trade is 13.3% of the 7,547 shares held after it.
- 4 other insiders bought within 30 days.
- 200 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RANDLE STUART A bought about $115.9K of TFX on Aug 5, 2025, the largest insider purchase at the company since 2021; 4 other insiders bought within 30 days and 200 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 30, 2021.
- The trade is 13.9% of the 7,192 shares held after it.
- 4 other insiders bought within 30 days.
- 200 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Krakauer Andrew A bought about $115.2K of TFX on Aug 5, 2025, the largest insider purchase at the company since 2021; 4 other insiders bought within 30 days and 200 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Dec 27, 2023.
- The trade is 3.3% of the 45,267 shares held after it.
- 4 other insiders bought within 30 days.
- 200 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, President & CEO Kelly Liam bought about $172.6K of TFX on Aug 5, 2025, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 200 funds added in the latest 13F quarter.30 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
200 funds bought in last quarter
more than 83% of Medical Devices
Revenue
+17.2% year over year
more than 67% of Medical Devices
Margin
-45.4% net margin
below 67% of Medical Devices
Buybacks
$250.0M repurchased, FY to 2026-06-30
more than 73% of Medical Devices
Short interest
9.6% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
more than 88% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TFX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+6.2%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TFX: institutional holders (13F)
13F holdings, latest reported quarter
5,431,818 sh
$688.5M
4,342,512 sh
$550.5M
2,416,998 sh
$306.4M
1,995,717 sh
$253.0M
1,526,228 sh
$193.5M
Congress trades in TFX
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-07-22 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-07-16 · disclosed 28 days later
$1,001 - $15,000
Sold 2025-02-25 · disclosed 30 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TFX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TFX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
MONONGAHELA ALL CAP VALUE FUND
$2.1M position · as of 2026-07-31
4.4%
Global Endurance Portfolio
$668.3K position · as of 2026-06-30
4.1%
Pzena Small Cap Value Fund
$3.1M position · as of 2026-05-31
3.3%
Invesco S&P SmallCap Health Care ETF
$4.0M position · as of 2026-05-31
3.0%
Heartland Value Fund
$24.2M position · as of 2026-06-30
2.1%
DIAMOND HILL SMALL-MID CAP FUND
$12.0M position · as of 2026-06-30
1.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
1
Phase 4
1 active
6
Not applicable
3 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Liam J. Kelly
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.7M
$1.8M
$1.7M
-69%
+23%
2024
$9.2M
$2.7M
$2.5M
-52%
+35%
2023
$9.0M
$9.3M
$2.3M
-33%
+23%
2022
$8.2M
$5.0M
$2.0M
-33%
+12%
2021
$8.7M
$4.2M
$2.1M
-12%
+42%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 200 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TFX financials
Revenue growth
+17.2%
XBRL, annual
Net margin
-45.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Revenue, TTM TFX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $3.0B |
| FY Dec 2022 | $2.8B |
| FY Dec 2021 | $2.8B |
| Jun 2026 | $570.3M |
| Mar 2026 | $548.3M |
| Dec 2025 | $569.0M |
| Sep 2025 | $913.0M |
| Jun 2025 | $780.9M |
| Mar 2025 | $700.7M |
| Dec 2024 | $442.0M |
| Sep 2024 | $764.4M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM TFX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +12.0% |
| FY Dec 2022 | +13.0% |
| FY Dec 2021 | +17.3% |
| Jun 2026 | +17.5% |
| Mar 2026 | -1.5% |
| Dec 2025 | -125.5% |
| Sep 2025 | -44.8% |
| Jun 2025 | +15.7% |
| Mar 2025 | +13.6% |
| Dec 2024 | -30.9% |
| Sep 2024 | +14.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM TFX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.97x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity TFX
| FY Dec 2025 | 0.85x |
| FY Dec 2024 | 0.39x |
| FY Dec 2023 | 0.41x |
| FY Dec 2022 | 0.43x |
| FY Dec 2021 | 0.49x |
| Jun 2026 | 0.97x |
| Mar 2026 | 0.85x |
| Dec 2025 | 0.85x |
| Sep 2025 | 0.70x |
| Jun 2025 | 0.45x |
| Mar 2025 | 0.47x |
| Dec 2024 | 0.39x |
| Sep 2024 | 0.39x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt TFX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-28.9%
TTM net income over average of 2025-06-29 and 2026-06-30
Return on equity TFX
| FY Dec 2025 | -24.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +8.5% |
| FY Dec 2022 | +9.3% |
| FY Dec 2021 | +13.7% |
| Jun 2026 | -28.9% |
| Mar 2026 | -28.1% |
| Dec 2025 | -24.5% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +5.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-14.6%
TTM net income over average of 2025-06-29 and 2026-06-30
Return on assets TFX
| FY Dec 2025 | -12.9% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +4.9% |
| FY Dec 2022 | +5.3% |
| FY Dec 2021 | +6.9% |
| Jun 2026 | -14.6% |
| Mar 2026 | -14.5% |
| Dec 2025 | -12.9% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +3.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital TFX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +3.5% |
| FY Dec 2022 | +7.8% |
| FY Dec 2021 | +10.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+0.7%
operating income (EBIT proxy) over average of 2025-06-29 and 2026-06-30 minus current liabilities
Return on capital employed TFX
| FY Dec 2025 | +1.9% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +3.9% |
| FY Dec 2022 | +8.0% |
| FY Dec 2021 | +9.8% |
| Jun 2026 | +0.7% |
| Mar 2026 | +1.0% |
| Dec 2025 | +1.9% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -1.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TFX
| FY Dec 2025 | n/a |
| FY Dec 2024 | 123.60x |
| FY Dec 2023 | 33.16x |
| FY Dec 2022 | 32.46x |
| FY Dec 2021 | 32.08x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 27.98x |
| Mar 2025 | 43.20x |
| Dec 2024 | 123.60x |
| Sep 2024 | 49.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$8.4B
market value at close 2026-10-27 on 2026-08-04 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value TFX
| FY Dec 2025 | $7.7B |
| FY Dec 2024 | $9.7B |
| FY Dec 2023 | $13.3B |
| FY Dec 2022 | $13.1B |
| FY Dec 2021 | $16.8B |
| Jun 2026 | $8.1B |
| Mar 2026 | $7.6B |
| Dec 2025 | $7.7B |
| Sep 2025 | $7.6B |
| Jun 2025 | $6.9B |
| Mar 2025 | $8.0B |
| Dec 2024 | $9.7B |
| Sep 2024 | $13.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield TFX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TFX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.72x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.0B | $3.0B | $3.0B | $2.8B |
| Gross profit | $1.1B | $1.0B | $1.0B | $1.5B |
| Operating income | $118.4M | $103.7M | $258.7M | $499.7M |
| Net income | -$905.6M | $70.2M | $357.6M | $363.1M |
| EPS (diluted) | -20.25 | 1.48 | 7.53 | 7.68 |
| Cash | $378.6M | $247.9M | $222.8M | $292.0M |
| Long-term debt | $2.5B | $1.6B | $1.7B | $1.6B |
| Buybacks | $300.0M | $200.0M | $0 | $0 |
| Dividends paid | $60.3M | $63.5M | $63.9M | $63.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
TFX Stock Sonar score 5/7 axes
Find similar shapesCompareTFX ranks highest on institutional and government (70th percentile) and growth (67th), and lowest on financial health (19th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TFX filings, in plain words
Have members of Congress traded TFX?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Lisa McClain dated 2025-07-22.
Read the full summary
Members of Congress have disclosed trades in TFX, none in the last year; the latest on record is a sale by Lisa McClain dated 2025-07-22. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
